

Release of restricted securities from escrow

16 October 2020

In accordance with ASX Listing Rule 3.10A, 4DMedical Limited (ASX: 4DX) ("**Company**") advises that 734,106 securities in the Company (ASX Code: 4DXAB) ("**Shares**") and 2,256,775 securities in the Company (ASX Code: 4DXAH) ("**Options**"), classified as restricted securities at the time that the Company was admitted to the official list of ASX, will be released from escrow on 26 October 2020.

The Company will apply for quotation of the Shares, and the Options will remain unquoted.

ENDS

Authorised by Charlene Stahr, Company Secretary.

Contacts:

Corporate

Charlene Stahr
Company Secretary
companysecretary@4dmedical.com

Investor

Simon Hinsley
+ 61 401 809 653
shinsley@4dmedical.com

Media

Matthew Wright
+ 61 451 896 420
matt@nwrcommunications.com.au

About 4DMedical:

Based in Melbourne, Australia and Los Angeles, USA, 4DMedical (formerly 4Dx) was founded in 2012 and is listed on the Australian Securities Exchange (ASX: 4DX).

4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to assist in providing sensitive, early diagnosis, and to monitor changes over time. Our Software-as-a-Service (SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods.

Respiratory diagnosis is a US\$31 billion per annum global industry. Through its technology 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctors and patients about lung function. Better information means better decisions, and better outcomes.